Sandoz Acquires US Biosimilar Cimerli

Sandoz Acquires US Biosimilar Cimerli

By, Admin 5 March 2024

Sandoz completes acquisition of Cimerli business from Coherus BioSciences

Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of anticipated timelines. The acquisition builds on the leading Sandoz ophthalmic platform in the US and lays an even stronger foundation for future product launches.

Word from Sandoz

Keren Haruvi, president Sandoz North America said: “Today we further expand the Sandoz biosimilar portfolio, while advancing our mission in the US of pioneering patient access to more affordable and much-needed medicines. With the addition of Cimerli to our existing ophthalmology franchise, we can now offer even more treatment options for US patients with vision impairment and loss.”

Indication 

Cimerli is indicated for the treatment of certain retinal diseases that, if left untreated, can cause vision loss, which ranks among the top 10 causes of disability in the United States. It is an anti-VEGF therapy within a class of biologics that helps retinal patients maintain or gain vision.

About Agreement

  • Sandoz and Coherus entered into an agreement in January 2024 through which Sandoz agreed to acquire the full Cimerli business for an upfront cash purchase price of USD 170 million. 
  • The transaction includes a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software.

About Cimerli Solution

  • Cimerli solution for injection (6 mg/mL and 10 mg/mL) is an FDA-approved biosimilar to reference product Lucentis (ranibizumab injection) indicated for the treatment of multiple retinal diseases, including neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) and myopic choroidal neovascularization (mCNV).3 Cimerli is an anti-VEGF therapy within a class of biologics that helps retinal patients maintain or gain vision. 
  • Cimerli was approved by the FDA in August 2022, having met FDA’s rigorous standards of biosimilarity to the reference product, including safety, efficacy and quality. 
  • Launched in October 2022, it is the first and only FDA-approved biosimilar interchangeable with Lucentis for all indications.

About Sandoz

  • Sandoz is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. 
  • 22,000 people of more than 100 nationalities work together to bring Sandoz medicines to some 500 million patients worldwide, generating substantial global healthcare savings and an even larger total social impact.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!